- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Ibrutinib (cll/sll) – November 2016
Ibrutinib (CLL/SLL): 140 mg capsules, 90; Imbruvica®
Last updated
30 June 2017